Filing Flows › ELI Lilly (LLY) › Guidance history
ELI Lilly (LLY) guidance history: what it guided and what it reported
ELI Lilly gave guidance in 12 earnings releases on file since Apr 30, 2024. Of 4 guided periods since reported, it met or beat its own guidance twice (50%). Revenue: 1 of 2, on average +0.8% against the guided midpoint. Its releases raised guidance 9 times and lowered it twice.
Revenue
Met or beat 1 of 2 periods (1 above, 0 within, 1 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $80.0B–$83.0B (Feb 4, 2026) → raised $82.0B–$85.0B (Apr 30, 2026) → raised $85.0B–$87.0B (Aug 5, 2026) → raised $91.0B–$92.0B (Oct 29, 2026) | — | to be reported | — |
| FY2025 | $58.0B–$61.0B (Jan 14, 2025) → reaffirmed $58.0B–$61.0B (Feb 6, 2025) → reaffirmed $58.0B–$61.0B (May 1, 2025) → raised $60.0B–$62.0B (Aug 7, 2025) → raised $63.0B–$63.5B (Oct 30, 2025) | $65.2B | above the range | +3.0% |
| FY2024 | $42.4B–$43.6B (Apr 30, 2024) → raised $45.4B–$46.6B (Aug 8, 2024) → lowered $45.4B–$46.0B (Oct 30, 2024) | $45.0B | below the range | -1.4% |
Tax rate
Met or beat 1 of 2 periods (1 above, 0 within, 1 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | 16.0% (Feb 6, 2025) → raised 17.0% (May 1, 2025) | 19.8% | above the range | +2.8 pts |
| FY2024 | 14.0% (Apr 30, 2024) → raised 15.0% (Aug 8, 2024) → raised 17.0% (Oct 30, 2024) | 16.5% | below the range | -0.5 pts |
Adjusted tax rate
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | 17.0% (Aug 7, 2025) | — | — | — |
GAAP EPS
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $20.85–$22.10 (Aug 7, 2025) → raised $21.80–$22.50 (Oct 30, 2025) | — | — | — |
| FY2024 | $1.25 (Apr 30, 2024) → raised $2.05 (Aug 8, 2024) → raised $12.05–$12.55 (Oct 30, 2024) | — | — | — |
Other income
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $600M–$700M (Feb 6, 2025) | — | — | — |
| FY2024 | −$500M–−$400M (Apr 30, 2024) → raised −$425M–−$325M (Oct 30, 2024) | — | — | — |
GAAP other income
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $750M–$850M (May 1, 2025) → lowered $650M–$750M (Aug 7, 2025) → lowered $600M–$700M (Oct 30, 2025) | — | — | — |
The latest quarter
ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart follows the revenue to costs, profit and cash.
Questions
Does ELI Lilly beat its guidance?
ELI Lilly gave guidance in 12 earnings releases on file since Apr 30, 2024. Of 4 guided periods since reported, it met or beat its own guidance twice (50%). Revenue: 1 of 2, on average +0.8% against the guided midpoint.
How often does ELI Lilly raise guidance?
Its earnings releases raised guidance 9 times and lowered it twice since Apr 30, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.